.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,048,899

« Back to Dashboard

Details for Patent: 6,048,899

Title: Anticonvulsant enantiomeric amino acid derivatives
Abstract:The present invention is directed to N-benzyl-2-amino-3-methoxypropionamide and stereoisomers the use thereof anti-convulsant and an intermediate in the preparation of other anti-convulsants.
Inventor(s): Kohn; Harold (Houston, TX), Andurkar; Shridhar V. (Houston, TX)
Assignee: Research Corporation Tech., Inc. (Tucson, AZ)
Filing Date:Jun 29, 1998
Application Number:09/107,206
Claims:1. A compound of the formula: ##STR8## or pharmaceutically acceptable salts thereof.

2. The compound of claim 1 which is in the R configuration.

3. A substantially pure compound of claim 1.

4. A substantially pure compound of claim 2.

5. The compound of claim 2 which is substantially enantiopure.

6. A pharmaceutical composition comprising an anti-convulsant effective amount of the compound according to claim 1 and a pharmaceutical carrier therefor.

7. The pharmaceutical composition according to claim 6 wherein said compound is in the R-configuration.

8. The pharmaceutical composition according to claim 6 wherein said compound is substantially pure.

9. The pharmaceutical composition according to claim 7 wherein said compound is substantially pure.

10. The pharmaceutical composition according to claim 7 wherein the compound is substantially enantiopure.

11. A method of treating central nervous system disorders in an animal comprising administering to said animal in need thereof an anti-convulsant effective amount of a compound according to claim 1.

12. The method according to claim 11 wherein the compound is in the R configuration.

13. The method according to claim 11 wherein the animal is a mammal.

14. The method according to claim 13 wherein the mammal is human.

15. The method according to claim 12 wherein the animal is a mammal.

16. The method according to claim 15 wherein the mammal is human.

17. The method according to claim 11 wherein the compound is substantially pure.

18. The method according tc claim 12 wherein the compound is substantially pure.

19. The method according to claim 12 wherein the compound is substantially enantiopure.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc